Esperion Therapeutics Inc. (ESPR) Jumps 6.79% on February 01

Equities Staff |

Esperion Therapeutics Inc. (ESPR) was among the biggest gainers on the Russell 2000 for Monday February 01 as the stock popped 6.79% to $15.89, representing a gain of $1.01 per share. Some 334,391 shares traded hands on 3,365 trades, compared with an average daily volume of 914,787 shares out of a total float of 22.52 million. The stock opened at $14.79 and traded with an intraday range of $16.00 to $14.45.

After today's gains, Esperion Therapeutics Inc. reached a market cap of $357.83 million. Esperion Therapeutics Inc. has had a trading range between $120.96 and $12.61 over the last year, and it had a 50-day SMA of $22.12 and a 200-day SMA of $55.52.

Esperion Therapeutics Inc is engaged in the research, development and commercialization of therapies for the treatment of patients with elevated levels of elevated levels of LDL-C.

Esperion Therapeutics Inc. is based out of Ann Arbor, MI and has some 21 employees. Its CEO is Timothy M. Mayleben.

For a complete fundamental analysis analysis of Esperion Therapeutics Inc., check out’s Stock Valuation Analysis report for ESPR. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets


Spotify is a online music service offering providing digital content from a range of record labels and artists. Users can browse through the interface by artist, album, genre, playlist, record…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…